Vir Biotechnology Q2 2024 Adj EPS $(1.02) Misses $(0.90) Estimate, Sales $3.10M Miss $7.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Vir Biotechnology (NASDAQ:VIR) reported Q2 2024 adjusted EPS of $(1.02), missing the $(0.90) estimate by 13.33%. Sales were $3.10M, missing the $7.50M estimate by 58.65% and down 18.36% from last year's $3.80M.
August 01, 2024 | 8:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vir Biotechnology reported disappointing Q2 2024 results with an adjusted EPS of $(1.02), missing the $(0.90) estimate by 13.33%. Sales were $3.10M, significantly below the $7.50M estimate and down 18.36% YoY.
The significant miss on both EPS and sales estimates, along with a year-over-year decline in sales, is likely to negatively impact Vir Biotechnology's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100